KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Interest & Investment Income: 2017-2025

Historic Interest & Investment Income for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to -$62.8 million.

  • Amneal Pharmaceuticals' Interest & Investment Income rose 4.12% to -$62.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$246.5 million, marking a year-over-year increase of 3.89%. This contributed to the annual value of -$258.6 million for FY2024, which is 22.77% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Interest & Investment Income stood at -$62.8 million for Q3 2025, which was up 3.51% from -$65.1 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Interest & Investment Income ranged from a high of -$33.3 million in Q1 2022 and a low of -$65.7 million during Q2 2024.
  • Moreover, its 3-year median value for Interest & Investment Income was -$61.7 million (2024), whereas its average is -$59.5 million.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Interest & Investment Income grew by 15.07% in 2021 and then slumped by 47.94% in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Interest & Investment Income (Quarterly) stood at -$34.0 million in 2021, then crashed by 38.49% to -$47.0 million in 2022, then decreased by 26.62% to -$59.5 million in 2023, then declined by 3.55% to -$61.7 million in 2024, then climbed by 4.12% to -$62.8 million in 2025.
  • Its Interest & Investment Income was -$62.8 million in Q3 2025, compared to -$65.1 million in Q2 2025 and -$56.9 million in Q1 2025.